|
| Press Releases |
|
 |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
|
雲頂新耀宣佈耐賦康(R)獲得中國國家藥品監督管理局完全批准 全面拓展IgA腎病治療人群 |
| 今日，雲頂新耀（HKEX: 1952.HK）宣佈，其核心產品耐賦康(R)（布地奈德腸溶膠囊，NEFECON(R)）正式獲得中國國家藥品監督管理局（NMPA）完全批准。 more info >> |
|
|
云顶新耀宣布耐赋康(R)获得中国国家药品监督管理局完全批准 全面拓展IgA肾病治疗人群 |
| 今日，云顶新耀（HKEX: 1952.HK）宣布，其核心产品耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）正式获得中国国家药品监督管理局（NMPA）完全批准。 more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
|
雲頂新耀「摘B」成功 盈利能力與創新價值獲雙重驗證 |
| 今日，雲頂新耀（HKEX 1952.HK）宣佈公司已獲香港聯交所批准，將「B」標記從股票代碼中移除 more info >> |
|
|
云顶新耀"摘B"成功 盈利能力与创新价值获双重验证 |
| 今日，云顶新耀（HKEX 1952.HK）宣布公司已获香港联交所批准，将"B"标记从股票代码中移除。 more info >> |
|
| Wednesday, March 19, 2025 |
|
|
雲頂新耀啟動嘉善工廠伊曲莫德生產建設項目 加速本地化供應佈局 |
| 今日，雲頂新耀宣佈正式啟動伊曲莫德（VELSIPITY(R)）位於嘉善工廠的生產建設項目，以支持該藥物的本地化生產，進一步滿足中國及亞洲市場對潰瘍性結腸炎（UC）治療的需求。該項目總投資達7000萬元，預計投產後年產能可達5000萬片，供應範圍涵蓋中國大陸、中國香港、中國澳門、中國台灣、韓國及新加坡等市場。 more info >> |
|
|
云顶新耀启动嘉善工厂伊曲莫德生产建设项目 加速本地化供应布局 |
| 今日，云顶新耀宣布正式启动伊曲莫德（VELSIPITY(R)）位于嘉善工厂的生产建设项目，以支持该药物的本地化生产，进一步满足中国及亚洲市场对溃疡性结肠炎（UC）治疗的需求。该项目总投资达7000万元，预计投产后年产能可达5000万片，供应范围涵盖中国大陆、中国香港、中国澳门、中国台湾、韩国及新加坡等市场。 more info >> |
|
| Monday, March 10, 2025 |
|
|
雲頂新耀「AI+創新藥」第一股成港股18A黑馬 |
| 近年來，AI賦能創新藥研發已成為全球生物醫藥行業的重要趨勢，尤其在mRNA疫苗領域，AI更是成為提升研發效率與精准度的核心驅動力。 more info >> |
|
|
云顶新耀"AI+创新药"第一股成港股18A黑马 |
| 近年来，AI赋能创新药研发已成为全球生物医药行业的重要趋势，尤其在mRNA疫苗领域，AI更是成为提升研发效率与精准度的核心驱动力。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Unlocking the Full Potential of GCCs: The Strategic Power of Cultural Integration
May 9, 2025 02:53 HKT/SGT
|
|
|
India: Revolutionizing Video And Content For The Global Media And Entertainment Industy
May 9, 2025 02:14 HKT/SGT
|
|
|
Guangzhou Electrical Building Technology 2025 brings industry leaders together to shape a low-carbon, intelligent building future
May 9, 2025 01:45 HKT/SGT
|
|
|
DigiTech ASEAN Thailand Returns this November as Demands for Digital and AI-Driven Solutions Grow
May 9, 2025 01:00 HKT/SGT
|
|
|
Thailand, Led by DPM Prasert, to Showcase Leadership in Hosting the 3rd UNESCO Global Forum on the Ethics of AI 2025
May 9, 2025 00:10 HKT/SGT
|
|
|
英國認證「保護者號」為首個同類遠程操控飛行器
May 9, 2025 00:00 HKT/SGT
|
|
|
英国认证“保护者”号为首个同类远程操控飞行器
May 9, 2025 00:00 HKT/SGT
|
|
|
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft
May 9, 2025 00:00 HKT/SGT
|
|
|
Ensign InfoSecurity Recognised in MITRE's 2024 Impact Report for Contribution to Global Cyber Defence Research
May 8, 2025 23:23 HKT/SGT
|
|
|
The 33rd China Cycle 2025 Grandly Commence
May 8, 2025 17:00 HKT/SGT
|
|
|
Aster Guardians Global Nursing Award Unveils Top 10 Finalists for 2025 from 100,000+ Registrations
May 8, 2025 16:54 HKT/SGT
|
|
|
TOYOTA、2025年3月期 決算発表
May 8, 2025 14:00: JST
|
|
|
2025年 Aster守護者全球護理獎公佈十大入圍決賽選手，逾10萬人報名參賽
May 8, 2025 13:00 HKT/SGT
|
|
|
2025年 Aster守护者全球护理奖公布十大入围决赛选手，逾10万人报名参赛
May 8, 2025 13:00 HKT/SGT
|
|
|
Malaysia Cybersecurity Center of Excellence Marks First Anniversary with New Partnerships, Scholarships and Expanded Programs
May 8, 2025 12:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
